中西降脂药物治疗动脉粥样硬化研究的现状  

Research status of atherosclerosis treated by traditional Chinese and western lipid-lowering drugs

作　　者：于晓东 杨飞云 刘美霞[1] YU Xiao-dong;YANG Fei-yun;LIU Mei-xia(Department of Cardiology,People's Hospital of Hebei Province,Shijiazhuang,Hebei,050000,China)

机构地区：[1]河北省人民医院心血管内科,河北石家庄050000

出　　处：《心血管康复医学杂志》2022年第3期387-391,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：脂质代谢紊乱及免疫炎症反应是导致动脉粥样硬化(AS)最重要的病理机制。大量研究证明降脂药物可影响血管内皮细胞的完整性,抑制免疫炎症反应,以及促使粥样斑块稳定,从而延缓AS的发展,是AS治疗中必不可少的组成部分。本文就目前临床常见中西降脂药物在AS治疗过程中的应用现状予以综述。Lipid metabolism disorder and immune inflammation response are the most important pathologic mechanisms leading to atherosclerosis(AS).A large number of studies have proved that lipid-lowering drugs can affect the integrity of vascular endothelial cells,inhibit immune inflammatory response,and prompt the stabilization of atherosclerotic plaque,thus delaying AS development,which is an essential part of AS treatment.The present article makes a review on application present situation of frequent Chinese and western lipid-lowering drugs in the treatment of AS.

关 键 词：心血管药物(中药) 调脂药 动脉粥样硬化 药物疗法 联合 

分 类 号：R543.5[医药卫生—心血管疾病]